{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.0","upperLimit":"84.9","value":"75.9"},{"comment":"NA: Confidence Interval could not be calculated for only1 participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Percentage of participants who achieved CR or CRi response with bone marrow MRD negative (MRD \\< 0.01%) after tisagenlecleucel infusion by flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"NUMBER","populationDescription":"FAS: The Full analysis set comprised all patients who received infusion of tisagenlecleucel","reportingStatus":"POSTED","timeFrame":"28 days","title":"Bone Marrow MRD Status by Flow Cytometry Per IRC Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}